A growing body of research suggests that use of a phosphoinositide 3-kinase inhibitor (PI3Ki) in conjunction with ET may improve response rates and progression-free survival in PIK3CA-mutant, estrogen receptor positive (ER+) BC relative to ET alone [7, 9–12], precluding or delaying the need for CT. The gene discussed is ESR1; the disease is breast cancer.